ProHance
Total Payments
$340,317
Transactions
24
Doctors
13
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $170,937 | 1 | 0 |
| 2022 | $3,731 | 6 | 4 |
| 2021 | $22,954 | 8 | 6 |
| 2020 | $107,238 | 5 | 1 |
| 2019 | $35,457 | 4 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $288,803 | 8 | 84.9% |
| Consulting Fee | $22,878 | 4 | 6.7% |
| Honoraria | $15,000 | 1 | 4.4% |
| Grant | $5,000 | 1 | 1.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,691 | 1 | 1.4% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000 | 1 | 0.9% |
| Food and Beverage | $715.67 | 7 | 0.2% |
| Travel and Lodging | $228.88 | 1 | 0.1% |
Payments by Type
Research
$288,803
8 transactions
General
$51,514
16 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED A GADOLINIUM-BASED CONTRAST AGENT (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE) | Bracco Diagnostics Inc. | $170,937 | 0 |
| Diagnostic Utility of MRI in Female Patients with Nipple Discharge: A Prospective Trial | Bracco Diagnostics Inc. | $104,238 | 0 |
| CAPABILITY OF ARTIFICIAL INTELLIGENCE TO DETECT MALIGNANCY IN LOW DOSE BREAST MRI | Bracco Diagnostics Inc. | $10,045 | 0 |
| Capability of Artificial Intelligence to Detect Malignancy in Low Dose Breast MRI | Bracco Diagnostics Inc. | $3,333 | 0 |
| An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Received a Gadolinium-Based Contrast Agent (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE) | Bracco Diagnostics Inc. | $250.00 | 0 |
Top Doctors Receiving Payments for ProHance
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $293,803 | 9 |
| , M.D., PH.D | Diagnostic Radiology | Baltimore, MD | $20,457 | 3 |
| , M.D | Diagnostic Radiology | Durham, NC | $15,000 | 1 |
| , MD | Diagnostic Radiology | Grand Rapids, MI | $4,691 | 1 |
| , M.D | Cardiovascular Disease | Brooklyn, NY | $3,000 | 1 |
| , MD | Nephrology | Philadelphia, PA | $2,250 | 1 |
| , MD | Nephrology | St George, VT | $400.00 | 1 |
| , MD | Diagnostic Radiology | Los Angeles, CA | $260.00 | 1 |
| , MD | Neuroradiology | Seattle, WA | $260.00 | 1 |
| , MD | Diagnostic Radiology | Columbia, TN | $48.00 | 1 |
| , MD | Family Medicine | Atlanta, GA | $37.08 | 1 |
| , MD | Pediatric Radiology | Tucson, AZ | $36.87 | 1 |
| , MD | Diagnostic Radiology | Phoenix, AZ | $36.86 | 1 |
| , MD | Diagnostic Radiology | Durham, NC | $36.86 | 1 |
Ad
Manufacturing Companies
- Bracco Diagnostics Inc. $291,803
- BRACCO DIAGNOSTICS INC. $48,514
Product Information
- Type Drug
- Total Payments $340,317
- Total Doctors 13
- Transactions 24
About ProHance
ProHance is a drug associated with $340,317 in payments to 13 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is BRACCO DIAGNOSTICS INC..
Payment data is available from 2019 to 2024. In 2024, $170,937 was paid across 1 transactions to 0 doctors.
The most common payment nature for ProHance is "Unspecified" ($288,803, 84.9% of total).
ProHance is associated with 5 research studies, including "AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED A GADOLINIUM-BASED CONTRAST AGENT (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE)" ($170,937).